"Imipenem" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
| Descriptor ID |
D015378
|
| MeSH Number(s) |
D02.065.589.099.124.300.500 D03.633.100.300.124.300.500
|
| Concept/Terms |
Imipenem- Imipenem
- N-Formimidoylthienamycin
- N Formimidoylthienamycin
- Imipemide
|
Below are MeSH descriptors whose meaning is more general than "Imipenem".
Below are MeSH descriptors whose meaning is more specific than "Imipenem".
This graph shows the total number of publications written about "Imipenem" by people in this website by year, and whether "Imipenem" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imipenem" by people in Profiles.
-
Evaluating the usefulness of the estimated glomerular filtration rate for determination of imipenem dosage in critically ill patients. S Afr Med J. 2022 08 30; 112(9).
-
Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest. Clin Microbiol Infect. 2022 Dec; 28(12):1650.e1-1650.e5.
-
Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints. Surg Infect (Larchmt). 2012 Feb; 13(1):43-9.
-
Appropriate use of the carbapenems. S Afr Med J. 2004 Oct; 94(10 Pt 2):857-61.
-
An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Int J Antimicrob Agents. 2001 Mar; 17(3):177-88.